top of page

Group

Public·9 members
Nolan Rivera
Nolan Rivera

Psychopharmacology: A Mental Health Professiona...


Most clients with DSM-5 diagnoses are being treated with a combination of psychological and pharmacological treatments. Newer drugs are being developed to treat mental disorders based on a better understanding of neurobiological contributions to mental disorders and the latest pharmacological research. To provide appropriate services, you are expected to have a thorough understanding of these common and complex issues. As a mental health professional, keeping up-to-date is essential.




Psychopharmacology: A mental health professiona...



**Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of mental health professionals. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your profession's standards. All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.


CSP 519 - Psychopharmacology for Mental Health Professionals Prerequisite, acceptance to the graduate program in school counseling, or school psychology, or emphasis in professional clinical counseling, or consent of instructor. This course meets one of the requirements for the emphasis in professional clinical counseling. The course is an overview of psychopharmacology, including the biological bases of behavior, neurophysiology, and an understanding of brain functions as related to behavior and learning. Emphases are placed on the biological principles of psychopharmacology, basic classifications, indications, and contraindications of commonly prescribed medications, and on the professional and ethical issues on the use of medications for the treatment of mental health disorders. (Offered as needed.) 3 credits


This jargon-free guide is suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes. A life-saving book that you can carry anywhere you go!


The central chapters provide comprehensive coverage of all the major medications used in the most common mental health disorders, detailing key drugs and including side effects, average doses, contra-indications and precautions, and clinical management interventions. Case studies, multiple choice questions and summary tasks in each chapter enable readers to clearly relate theory to practice and thoroughly review their learning.


Herbert Mwebe is a senior teaching fellow and a senior lecturer in mental health in the School of Health and Education at Middlesex University. Within the Department of Mental Health, Herbert delivers physical health training for both undergraduate and postgraduate programmes. He is the continuous professional development (CPD) programme lead in the Department of Mental Health, and his teaching and research interests focus on improving physical health in serious mental illness (SMI) as well as psychopharmacological interventions in mental health settings. Prior to entering academia, Herbert worked in inpatient, community and primary care settings. Within General Practice he led on a mental health project (PMS+ Mental Health Project) in City and Hackney commissioned by NHS England with a key function to provide timely management and treatment of people presenting with mental illness in primary care. Herbert is also a specialist clinical advisor to the Care Quality commission (CQC), a role in which he supports the CQC with community and hospital inspections for mental health and social care providers. He is also an editorial board member for the British Journal of Mental Health Nursing.


Her primary care doctor has recently prescribed her a Xanax-like drug for insomnia. She already talked about her physical symptoms with her doctor, and didn't think it applied to her mood or mental health...


"...an excellent first edition that pulls together helpful information for nonphysician mental health professionals who wish to learn more about psychiatric illnesses and pharmacologic treatment." (PsycCRITIQUES, December 6, 2006)


Join the latest advancement in the field of psychology; the practice of psychopharmacology. Employment in the mental health field is on the rise. Factors like increased awareness of mental health and a focus on rehabilitation over incarceration are driving this demand.1,2


Currently, five states in the U.S. allow psychologists, by law, to prescribe medications. The number is growing with several other states actively pursuing legislation. In those states where psychologists prescribe, their unique training and skill set are of high value and particular interest to rural and urban mental health facilities, general medical centers, as well as nationwide within the U.S. military, universities, and Urban Indian Health Centers.


The overall goals of the program are to educate practicing psychologists to work collaboratively with other health care professionals who prescribe medication, to integrate psychotropic medication and its management in treatment of behavioral and mental disorders, and to prescribe safely and effectively in states and federal agencies that allow psychologists to prescribe. California does not currently grant prescriptive authority to psychologists through a psychopharmacology program, while other states have granted prescriptive authority to psychologists as part of their licensure process. This program is designed to prepare licensed psychologists to prescribe safely and effectively in the states and federal jurisdictions in which they have prescriptive authority.


The Master of Science in Clinical Psychopharmacology (MSCP) is a two-year graduate degree program designed to educate students in psychopharmacology and medical conditions relevant to mental health care and psychological disorders. MCSP degree program students will learn how to increase their current competency in assessment, diagnosis, and intervention, and engage in case-based learning that will enhance their collaborative practice skills. The MCSP degree program at The Chicago School of Professional Psychology is designated by the American Psychological Association (APA).


As a mental health clinician and prescriber, I have had the distinct privilege of learning from one of the foremost authorities in the field of psychopharmacology, Joe Wegmann, R.Ph., LCSW. His clear, practical, and clinically-driven knowledge base has been invaluable in achieving the highest treatment outcomes for my clients.


In his most recent book, The Third Edition of Psychopharmacology : Straight Talk on Mental Health Medications, Joe delivers a comprehensive review on diagnosis, assessment and treatment strategies for the most common mental health syndromes. His unique focus on proper assessment to determine when is best to utilize psychopharmacology versus other forms of treatment has successfully individualized the care I provide. Every practicing mental health clinician should have this outstanding resource in their library.


ISU and the MSCP program share a vision with Optum Idaho in the role licensed psychologists will have with integrated healthcare in Idaho. A critical component of that vision is the shared goals of recovery and resiliency in mental health treatment in Idaho. The MSCP program training will enhance access to


Psychologists have always been leaders in the provision of quality mental and behavioral healthcare to their patients. As part of their commitment to continuity of care, psychologists are increasingly working collaboratively with physicians and other medical providers surrounding the psychopharmacological treatment of the individuals they serve. In the next step in this process, psychologists have achieved prescriptive authority in several states and other settings. Preliminary evidence finds them to be safe and effective prescribers. It has even been suggested that psychologists have an ethical obligation to continue their training in psychopharmacology and the impact of biological factors on emotional disorders (Barnett & Neel, 2000).


This 4-hour psychopharmacology training is perfect for new Masters' or PhD level behavioral health providers, or those looking for a refresher on basic pharmacologic treatment strategies for major mental health diagnoses. This course was written and presented by a psychiatrist and licensed clinical social worker. Treatment strategies that will be covered include: Depression; Anxiety; PTSD; Bipolar; and Delusional Parasitosis. Participants will also have the opportunity to learn more about the history of psychopharmacology and early interventions used, as well as, engage in a pertinent discussion on the ethical issues clinicians face as they integrate with primary care.


The TCSPP Master of Science in Clinical Psychopharmacology is a two-year program designed to educate students who wish to expand their knowledge base in psychopharmacology and medical conditions that are relevant to mental health care. Students will learn how to increase their current competency in assessment, diagnosis, and intervention, and engage in case-based learning that will enhance their collaborative practice skills.


This jargon-free book is suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes.


Whilst there are various alternative interventions to managing moderate to severe mental health presentations, psychotropic medications remain the mainstay interventions used in various clinical settings. These medicines have been around for over 5 decades with evidence showing that they help to lessen and improve the severity of psychiatric symptoms in people suffering with a mental illness. The arbiter of whether these medications are useful or not is the person taking the medication. Just like most drugs, psychiatric drugs produce benefits and risks for patients; it is the duty of the health professional to have a good understanding of the benefits and harm we expose patients to when psychiatric medication is considered as an intervention. 041b061a72


About

Welcome to the group! You can connect with other members, ge...

Members

bottom of page